Kronos Bio Inc. Stock News

Whether you're looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week wit

Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.57 per share a year ago.

Company presented positive preliminary data from Phase 1 dose escalation portion of  Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences

Strategic resource allocation to fully explore KB-0742's potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study

Brian Van Tine, M.D., of Washington University School of Medicine, shares data  from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical stud

Brian Van Tine, M.D., of Washington University School of Medicine to share data  from the ongoing Phase 1/2 study at leading international sarcoma meeting

Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope Management to host con

SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th

Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.65 per share a year ago.

Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Shares of Kronos Bio Inc. KRON, +2.38% jumped 25% in premarket trading on Monday after the company announced a development deal with Roche Holding's ROG, -0.46% Genentech. Kronos has a drug discovery

Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th

Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.